ROME raises $72m in Series B extension for lead programme development
The money raised from the Series B extension will be used by ROME to advance its LINE-1 reverse…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Sep 23
The money raised from the Series B extension will be used by ROME to advance its LINE-1 reverse…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Sep 23
Through the acquisition, the French firm adds VERT-002, a monoclonal antibody that targets and degrades c-MET, which is…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Sep 23
The financing is expected to drive Grit Biotechnology’s Phase 2 trial for GT101 and further development of next-generation…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Sep 23
With the transaction, Kriya now own Tramontane’s FGF21 assets, including the latter’s adeno-associated virus (AAV) vector programme, designed…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Sep 23
Abacavir/dolutegravir/lamivudine is a fixed-dose combination that consists of a pair of nucleoside reverse transcriptase inhibitors (NRTIs) and integrase…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Sep 23
The consent order agreement with FTC allows Amgen to complete its proposed $27.8bn acquisition of Horizon Therapeutics, while…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Sep 23
Upon completion of the acquisition, which is expected in the fourth quarter of this year, Mindset will become…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Aug 23
Novo Nordisk obtains full rights to develop and commercialise Embark Biotech’s lead programme, in exchange for €15m in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Aug 23
Timber Pharmaceuticals' primary investigational product candidate, known as TMB-001, is a topical reformulation of isotretinoin, the active ingredient
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Aug 23
The FDA approval is based on the Phase 3 MAGNITUDE study, in which Akeega plus prednisone significantly improved…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates